Literature DB >> 23914361

In memoriam: Norman S. Radin (1920-2013).

James A Shayman1.   

Abstract

Mesh:

Substances:

Year:  2013        PMID: 23914361      PMCID: PMC3679375          DOI: 10.1194/jlr.e039131

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


× No keyword cloud information.
  10 in total

1.  IN VIVO CONVERSIONS OF CEREBROSIDE AND CERAMIDE IN RAT BRAIN.

Authors:  K C KOPACZYK; N S RADIN
Journal:  J Lipid Res       Date:  1965-01       Impact factor: 5.922

2.  Biosynthesis of odd-and even-numbered cerebroside fatty acids: evidence for two routes.

Authors:  A K HAJRA; N S RADIN
Journal:  Biochim Biophys Acta       Date:  1963-02-19

3.  The preparative isolation of cerebrosides.

Authors:  N S RADIN; J R BROWN; F B LAVIN
Journal:  J Biol Chem       Date:  1956-04       Impact factor: 5.157

4.  The rôle of glycine in the biosynthesis of heme.

Authors:  N S RADIN; D RITTENBERG; D SHEMIN
Journal:  J Biol Chem       Date:  1950-06       Impact factor: 5.157

5.  The rôle of acetic acid in the biosynthesis of heme.

Authors:  N S RADIN; D RITTENBERG; D SHEMIN
Journal:  J Biol Chem       Date:  1950-06       Impact factor: 5.157

6.  The enzymatic formation of sphingomyelin from ceramide and lecithin in mouse liver.

Authors:  M D Ullman; N S Radin
Journal:  J Biol Chem       Date:  1974-03-10       Impact factor: 5.157

7.  Synthesis of cerebroside by brain from uridine diphosphate galactose and ceramide containing hydroxy fatty acid.

Authors:  P Morell; N S Radin
Journal:  Biochemistry       Date:  1969-02       Impact factor: 3.162

8.  Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain.

Authors:  R R Vunnam; N S Radin
Journal:  Chem Phys Lipids       Date:  1980-04       Impact factor: 3.329

9.  Preparation of the active isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, inhibitor of murine glucocerebroside synthetase.

Authors:  J Inokuchi; N S Radin
Journal:  J Lipid Res       Date:  1987-05       Impact factor: 5.922

10.  ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease.

Authors:  J A Shayman
Journal:  Drugs Future       Date:  2010-08-01       Impact factor: 0.148

  10 in total
  1 in total

1.  Pharmacotherapy of Gaucher Disease: Current and Future Options.

Authors:  Lunawati L Bennett; Chris Fellner
Journal:  P T       Date:  2018-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.